- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05728541
Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of SYH2043 in Patients With Advanced Malignant Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is an open-label, single-arm, multi-center Phase I clinical study, which includes four stages:
A: Dose-escalation Stage: The dose escalation stage is divided into 5 dose levels, and a Bayesian Optimal Interval Design (BOIN) including accelerated titration will be used for dose escalation.
B: PK Expansion Stage: Two or three dose groups will be selected for PK expansion; After PK extension the cohort extension study will be conducted as required, and will include 4 cohorts according to the tumor types.
C: Combination dose Escalation: This study will use a 3+3 design with up to 2 dose escalation cohorts at increasing levels.
D: According to the results of stage C, 1-2 combination doses will be selected for combination dose expansion, and Simon 2 stage was adopted for the expansion stage.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Patients aged 18-75 years (inclusive);
- 2. Histological or cytological confirmation of advanced malignant tumors;
3. Patients who failed or were intolerant to standard treatment or had no standard treatment, and meet the criteria as below of the corresponding stages:
- Part A and PK Expansion Stage of part B: advanced malignant tumors;
- Cohort extension of part B: solid tumors such as locally advanced/metastatic breast cancer, relapsed/refractory ovarian cancer, locally advanced/metastatic liver cancer, etc;
- Part C and D: locally advanced/metastatic breast cancer with histological confirmation of ER+, HER2-;
- 4. With at least one measurable lesion according to RECIST v1.1;
- 5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1;
- 6. Life expectancy greater than 3 months;
7. Main organs meet the following criteria within 7 days before treatment:
- Hematology: no component blood transfusion, human granulocyte colony-stimulating factor (G-CSF), and erythropoietin (EPO) within 2 weeks prior to the investigational drug administration
- Absolute neutrophil count (ANC) ≥1.5×10^9/L;
- Platelet count (PLT) ≥90×10^9/L;
- Hemoglobin (HGB) ≥90 g/L or ≥5.6 mmol/L;
- Renal Function: Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 50 mL/min;
- Liver function: Total bilirubin (TBIL) ≤ 1.5×ULN, or ≤ 3×ULN for patients with Gilbert syndrome; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤ 2.5×ULN, or ≤ 5×ULN in case of liver metastases;
- Coagulation Function: Activated partial thromboplastin time (APTT)≤ 2×ULN; International normalized ratio (INR)≤ 2×ULN;
- 8. The serum pregnancy test for women of childbearing potential (WOCBP) is negative within 7 days prior to the first dose of the investigational drug. Patient and his/her spouse must agree to take adequate contraception from signing of ICF to 6 months after the last dose, during which women should be non-lactating and men should refrain from donating sperms;
- 9. Patients voluntarily participate in this clinical study, understand the study procedures and sign the ICF.
Exclusion Criteria:
- 1. Have received anti-tumor treatments such as chemotherapy, radiotherapy, endocrine therapy, targeted therapy, immunotherapy, etc. within 4 weeks before the first dose of the investigational drug;
- 2. Have received other unmarketed clinical investigational drugs or treatments within 4 weeks before the first dose of the investigational drug;
- 3. Have received major surgery (excluding needle biopsy), or severe unhealed wounds, trauma, etc. within 4 weeks before the first dose of the investigational drug in the study;
- 4. Have received glucocorticoids for systemic therapy over 7 days (Prednisone>10 mg/day or equivalent doses) or other immunosuppressant within 2 weeks before the first dose of investigational drug, and patients who need long-term use these therapies;
- 5. Have received potent inhibitors or inducers of CYP3A4 and inhibitors of P-gp within 1 weeks before the first dose of the investigational drug;
- 6. The adverse events due to previous anti-tumor treatments without recovering to Grade 1 (except for alopecia; some toxicities may be excluded as judged by the investigator) according to NCI-CTCAE v5.0;
- 7. Breast cancer patients with visceral crisis or symptomatic visceral metastasis;
- 8. With active central nervous system (CNS) metastasis and/or cancerous meningitis;
- 9. Active HBV or HCV infection (HbsAg positive and/or HBcAb positive with HBV DNA ≥ 2000 IU/mL, and HCVAb positive with HCV RNA positive), or HIV positive;
- 10. Participants with a history of severe cardiovascular disease;
- 11. Inability to swallow medications orally, or conditions that, in the judgment of the investigator, significantly affect gastrointestinal absorption;
- 12. Patients who have received a live attenuated vaccine within 2 weeks before the first use of the investigational drug or plan to receive during the study;
- 13. Other situations that the investigator considers not suitable for participating in the clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SYH2043
Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
|
Patients will receive SYH2043 once everyday on day 1-21 of each 28-day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AE
Time Frame: Up to approximately 3 years
|
Occurrence and frequency of Adverse Event
|
Up to approximately 3 years
|
SAE
Time Frame: Up to approximately 3 years
|
Serious Adverse Event
|
Up to approximately 3 years
|
DLT
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
Dose-limiting Toxicity (DLT)
|
At the end of Cycle 1 (each cycle is 28 days)
|
MTD
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
The maximum tolerated dose (MTD) (if available)
|
At the end of Cycle 1 (each cycle is 28 days)
|
RP2D
Time Frame: At the end of Stage A (approximately 1 year)
|
Recommended phase 2 dose (RP2D) in stage A
|
At the end of Stage A (approximately 1 year)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC
Time Frame: Up to approximately 3 years
|
Area under the plasma concentration versus time curve (AUC)
|
Up to approximately 3 years
|
Cmax
Time Frame: Up to approximately 3 years
|
Peak Plasma Concentration (Cmax)
|
Up to approximately 3 years
|
t1/2
Time Frame: Up to approximately 3 years
|
Half-life (t1/2)
|
Up to approximately 3 years
|
Tmax
Time Frame: Up to approximately 3 years
|
Time to peak drug concentration (Tmax)
|
Up to approximately 3 years
|
Vz/F
Time Frame: Up to approximately 3 years
|
Apparent volume of distribution
|
Up to approximately 3 years
|
CL/F
Time Frame: Up to approximately 3 years
|
Apparent clearance
|
Up to approximately 3 years
|
pRb
Time Frame: Up to approximately 3 years
|
Explore the relationship between phosphor-retinoblastoma protein (pRb) and efficacy
|
Up to approximately 3 years
|
ORR
Time Frame: Up to approximately 3 years
|
Objective Response Rate
|
Up to approximately 3 years
|
PFS
Time Frame: Up to approximately 3 years
|
Progression-free Survival
|
Up to approximately 3 years
|
OS
Time Frame: Up to approximately 3 years
|
Overall Survival
|
Up to approximately 3 years
|
DoR
Time Frame: Up to approximately 3 years
|
Duration of Response (DoR)
|
Up to approximately 3 years
|
DCR
Time Frame: Up to approximately 3 years
|
Disease Control Rate (DCR)
|
Up to approximately 3 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYH2043-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignant Tumors
-
Hangzhou Sumgen Biotech Co., Ltd.Recruiting
-
NovaRock Biotherapeutics, LtdRecruitingAdvanced Malignant TumorsChina
-
AkesoRecruiting
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Malignant TumorsChina
-
SUNHO(China)BioPharmaceutical CO., Ltd.RecruitingAdvanced Malignant TumorsChina
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Malignant TumorsChina
-
Atridia Pty Ltd.CompletedAdvanced Malignant TumorsAustralia
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
AnewPharmaCompletedAdvanced Malignant Solid TumorsChina
-
SUNHO(China)BioPharmaceutical CO., Ltd.RecruitingAdvanced Malignant TumorsChina